Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 AUG 3 ... in this study. About CINV Prevention and control of nausea and vomiting, or emesis, are very important in the treatment of cancer patients. The majority of patients ...
2009 NOV 23 ... and colleagues. The researchers concluded: "We documented nausea and emesis in one and elevation of liver enzymes in another patient that were likely to be ...
2009 OCT 19 ... agents has, to date, been limited by adverse effects including nausea and emesis, making accurate assessment of emetic versus anti-inflammatory potencies critical to the ...
2009 AUG 31 ... and four contrast studies per patient. These patients presented with protracted biliary emesis and a clinical picture of bowel obstruction. Irrespective of time to diagnosis, all ...
2009 AUG 24 ... of an anthracycline and cyclophosphamide (AC) and failing to achieve complete control of emesis. Eligibility: breast cancer patients receiving their first cycle of AC." ...
2009 AUG 10 ... and safety of casopitant for treatment of chemotherapy-induced acute and delayed emesis, as well as the postoperative nausea/vomiting. Although preclinical studies promoted the ...
2009 OCT 5 ... abdominal distention, and increased gastric residual volume, along with an episode of emesis. The hospital nutritional-support service is consulted for feeding recommendations. A ...
2009 AUG 4 ... previously found a significant peripheral component in neurokinin NK1-receptor mediated emesis, the authors undertook this study to examine the putative central component," ...
2009 NOV 16 ... Single dose palonosetron achieves optimal control of acute emesis in patients receiving multiday-high dose chemotherapy before autologous stem cell ...
2009 OCT 12 ... 0.653 to 1.090; P = .1920). Although somewhat more neutropenia, elevations in AST/ALT, emesis, and fatigue occurred in the q3 weeks 24-hour, this regimen was reasonably well ...
2009 NOV 16 ... which was considered to be HEC. No significant differences in complete response (CR: no emesis and no rescue medication) rates were found in the first 24 h between the 0.075-, 0.25-, ...
2009 NOV 16 ... with Ond/Dex provided significant improvement in the prevention of cisplatin-induced emesis." Roila and colleagues published the results of their research in Annals ...
2009 AUG 18 ... excluded. Score components (right lower quadrant and hop tenderness, anorexia, pyrexia, emesis, pain migration, leukocytosis, and neutrophilia) were collected on standardized forms by ...
2009 AUG 3 ... vitamin B-6 PC6 points injection with acupuncture or vitamin B6 alone in controlling emesis of 142 patients undergoing a highly emetogenic chemotherapy regimen between March 1, ...
2009 AUG 24 ... high. All differences were statistically significant. Short-term complications included emesis (2 of 71), dysuria (5 of 71) and wound infection (2 of 71). Long-term complications were ...
2009 AUG 31 ... treatment with the 5-HT3 receptor antagonist for prophylaxis of chemotherapy-induced emesis remains to be clarified. A retrospective analysis was performed to compare the effects ...
2009 AUG 10 ... postural headaches, and occasionally with other symptomology as well, such as nausea, emesis, neck stiffness, and photophobia. In this case series, we present 4 patients who ...
2009 AUG 17 ... A favorable influence oil the patient satisfaction scores, and number needed to prevent emesis was seen in the 2 drug groups. No significant correlation was found between ...
2009 JUL 27 ... as the "preferred" 5-HT3 antagonist in the combined regimen recommended for emesis prevention in patients undergoing highly emetogenic chemotherapy (HEC). Last week, MASCC ...
2009 JUL 27 ... field sales organization. Given many patients suffering from pain also suffer from emesis, there is a good fit between MGX006 and Victory's growing, pain management franchise." ...
